$-0.41 EPS Expected for HTG Molecular Diagnostics, Inc. (HTGM); Fair Isaac Has 0.97 Sentiment

February 16, 2018 - By Vivian Currie

Fair Isaac Corporation develops analytic, software, and data management services and products that enable businesses to automate, enhance, and connect decisions. The company has market cap of $5.05 billion. The firm offers analytical solutions, credit scoring, and credit account management services and products to banks, credit reporting agencies, credit card processing agencies, insurers, retailers, healthcare organizations, and public agencies. It has a 45.68 P/E ratio. It operates through three divisions: Applications, Scores, and Decision Management Software.

Analysts expect HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) to report $-0.41 EPS on March, 22.They anticipate $0.35 EPS change or 46.05% from last quarter’s $-0.76 EPS. After having $-0.46 EPS previously, HTG Molecular Diagnostics, Inc.’s analysts see -10.87% EPS growth. The stock increased 1.58% or $0.08 during the last trading session, reaching $5.13. About 851,646 shares traded. HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) has risen 34.13% since February 16, 2017 and is uptrending. It has outperformed by 17.43% the S&P500.

The stock increased 1.39% or $2.31 during the last trading session, reaching $168.05. About 116,118 shares traded. Fair Isaac Corporation (FICO) has risen 27.37% since February 16, 2017 and is uptrending. It has outperformed by 10.67% the S&P500.

Since January 1, 0001, it had 0 insider purchases, and 1 insider sale for $1.03 million activity.

Banbury Partners Llc holds 8.52% of its portfolio in Fair Isaac Corporation for 247,895 shares. Profit Investment Management Llc owns 17,527 shares or 2.14% of their US portfolio. Moreover, Atlanta Capital Management Co L L C has 2.05% invested in the company for 2.58 million shares. The California-based Ami Asset Management Corp has invested 0.86% in the stock. Ghp Investment Advisors Inc., a Colorado-based fund reported 33,153 shares.

HTG Molecular Diagnostics, Inc. develops and markets services and products based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company has market cap of $142.84 million. The company's products, HTG Edge and HTG EdgeSeq platforms include instrumentation , consumables comprising assay kits, and software analytics that automate sample processing and profiles various molecular targets from samples a fraction of the size required by prevailing technologies. It currently has negative earnings. The Company’s platforms generate a molecular profiling library for detection using next-generation sequencing.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: